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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not are Dmannose pills an effective form of prophylaxis for women prone to recurrent urinary tract
infections?
Study Design: Systematic review of three randomized controlled trials (RCTs) published
between 2014-2016, all in the English language.
Data Sources: Three randomized controlled trials (RCTs) which evaluated the effectiveness of
D-mannose as prophylaxis against recurrent UTI in women as compared to control groups either
given no prophylaxis and or antibiotic prophylaxis. All studies were found using PubMed and
the Cochrane library.
Outcomes Measured: All three studies measured the number of patients that had a recurrent
UTI during the follow-up period. One study also measured the time to recurrence of UTI and
change in pain and urgency symptoms on the visual analog scale (VAS).
Results: All three studies found that patients were significantly less likely to have a UTI
recurrence with D-mannose compared to no agents for prophylaxis. One study found similar
efficacy of D-mannose and nitrofurantoin for prophylaxis; however, tolerability of D-mannose
was significantly better than that of nitrofurantoin. A third study found that D-mannose
prevented urinary tract infections better than trimethoprim-sulfamethoxazole (TMP-SMX),
however, dosing of TMP-SMX was suboptimal.
Conclusions: D-mannose was found to be effective in preventing recurrence of urinary tract
infections in women prone to such infections. Further studies are needed to determine optimal
dosing of D-mannose for prophylaxis. In addition, more studies conducting an adequate
comparison of D-mannose to conventional antimicrobial therapy are required before
implementing this supplement as standard of care.
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INTRODUCTION
A urinary tract infection (UTI) is a bacterial infection of the urinary tract that either
manifests as cystitis or migrates up the urinary tract into the kidney and causes pyelonephritis.
UTI is one of the most common infections occurring in females worldwide.1 Recurrent urinary
tract infection is defined as two culture-proven infections in 6 months or 3 in 12 months.1,2. UTIs
are most commonly caused by E. coli. Other less common pathogens include S. saprophyticus,
Klebsiella pneumoniae, and Proteus mirabilis.1 The condition is more common in females due to
anatomic features allowing easy ascent of fecal flora into the urinary tract. Recurrent urinary tract
infections can occur from persistence of bacteria after treatment of initial infection either due to
inadequate treatment, noncompliance, or high organismal counts. Recurrent infections can also
occur from recolonization of the urinary tract. Some patients may be predisposed to recurrent
UTI due to structural or functional abnormalities.
It is estimated that worldwide, nearly 150 million UTIs occur annually.3 The lifetime risk
of a female getting a UTI is 50%.1 About 36% of women younger than 55 and 53% of women
over 55 report recurrence in one year.1 Urinary tract infections are projected to cost over $6
billion annually3 and account for nearly 7 million office visits per year.4 A retrospective analysis
in Europe estimates a mean annual cost of $270 per patient for a UTI. This cost includes the
physician visit, diagnosis, and treatment of the condition.5 In addition to economic burden,
urinary tract infections, especially recurrent infections, are known to cause significant painful
symptoms and psychological distress in women.
Uncomplicated UTI is often treated with trimethoprim-sulfamethoxazole (TMP-SMX),
nitrofurantoin, ciprofloxacin, or cephalexin for 3-10 days depending on the selected therapy and
the patient. Recurrent UTI is treated with nightly or post-coital prophylaxis with TMP-SMX or
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nitrofurantoin. With the increasing advent of antibiotic resistance and adverse effects from
frequent or daily antibiotic use, alternative methods are necessary for preventing recurrent UTI, a
common, devitalizing condition.
D-mannose is a simple, natural sugar that inhibits bacterial adhesion to the urothelium.6
Bacterial fimbriae preferably bind D-mannose in the urine rather than proteins on the bladder
wall.6 Once bound, this complex is trapped in the urine and eliminated during urination and
therefore the bacteria cannot cause infection. This mechanism is especially relevant for the most
common UTI pathogen, E. coli, which exerts its virulence by attaching its fimbriae to the
urothelium to persist and proliferate in the urinary tract.1 D-mannose has been reported to relieve
lower urinary tract symptoms and prevent recurrence of UTI in women prone to the condition
without the use of antimicrobial therapy.6 This paper evaluates 3 randomized, controlled trials
(RCTs) evaluating the efficacy of D-mannose for prophylaxis against recurrent UTI in females
prone to this condition compared with no prophylactic therapy and conventional antimicrobials.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not are D-mannose
pills an effective form of prophylaxis for women prone to recurrent urinary tract infections?
METHODS
This systematic review uses three randomized controlled trials (RCTs). All articles were
researched using the Cochrane library and PubMed. Articles selected displayed relevance to this
topic and were required to study outcomes that were POEMs (patient-oriented evidence that
matters). These articles were found using keywords “D-mannose”, “urinary tract infection”, and
“women”. All three articles were published in peer-reviewed journals, and all were published in
English. Articles were published no earlier than 2007. Any studies using male subjects or
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subjects under age 18 were excluded. See Table 1 for inclusion and exclusion criteria specific to
each of the studies used in this review.
Table 1. Demographics and Characteristics of Included Studies
Study Type #
Age Inclusion
Exclusion Criteria
pts (yrs) Criteria
Dome RCT 45
18Women age 18- History of urinary
nici,
65
65 years,
tract anomaly, acute
20166
symptoms of
symptoms >1 week,
acute cystitis,
pregnant/breast
asymptomatic
feeding, trying to
with diagnosis
conceive,
3
of a UTI (10 or inflammatory UTI,
more colonyhormone replacement,
forming units
interstitial cystitis,
per mL)
DM, catheter use,
previously antibiotic
prophylaxis, unable to
fill out questionnaire
Kranj RCT 308 29Female
Pregnancy, breast
cec,
58
Age > 18 yrs
feeding, symptoms of
20142
Positive history upper UTI, symptoms
of recurrent
of inflammatory
cystitis
response, history of
urinary tract
anomalies, interstitial
cystitis, DM, use of
hormone therapy or
contraception,
previously had UTI
prophylaxis
Porru, RCT 60
22Female >18 yrs, Upper UTI and/or
20147
54
acute
temperature > 38˚ C,
symptomatic
flank/lumbar pain,
UTI, ≥ 3 UTIs
renal disease,
w. positive
anatomic
urine cultures in abnormalities, prior
the last 3
GYN surgery,
months, no
immunosuppressive
antimicrobials
medications or
within 4 weeks, diseases
not
pregnant/conte
mplating
pregnancy

W/ Interventions
D
2
D-mannose 1
week per
month, every
other month
for 6 months
No treatment

0

2 g Dmannose QHS
No
prophylaxis

0

D-mannose 3
g TID x 2
weeks then 1g
BID x 22
weeks
TMP-SMX
160/800 mg
BID x 5 days
then QHS for
23 weeks
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The population studied involved women over age 18 with history of recurrent urinary
tract infection, defined as 3 or more culture-proven urinary tract infections in 12 months. The
intervention being studied is D-mannose pills for prophylactic therapy against recurrent UTI.
Comparison in one study was no prophylaxis. The second study had two control groups: one
given prophylaxis with nitrofurantoin and one given no prophylaxis. The third study used one
control group given prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX). The major
outcome measured in these studies was whether or not the patient reported irritative voiding
symptoms consistent with the onset of an acute, recurrent UTI. Two of the studies confirmed the
reported infection with a urine culture to verify that symptoms were consistent with a true UTI
recurrence.
Data analysis of this study was conducted using the number of patients in each group
reporting urinary symptoms after initiation of the prophylactic regimen. One study also recorded
mean time to recurrence with standard deviation values as well as urinary pain and urgency on
the visual analog scale (VAS). Statistical analyses used include p-value, risk reduction, and 95%
confidence intervals.
OUTCOMES MEASURED
The studies measured the number of patients with a recurrence of UTI by patient-reported
irritative voiding symptoms. These symptoms included dysuria, frequency, urgency, nocturia,
hematuria, suprapubic pain, and low back pain. Kranjcec et al. and Porru et al. confirmed UTI
onset with a urine culture after patients reported symptoms. Porru et al. also recorded the mean
time to recurrence (TTR) of the UTI with standard deviation, and patient-reported pain and
urinary urgency on the visual analog scale (VAS) with standard deviation.
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RESULTS
Three RCTs were used to determine whether D-mannose is an effective agent for
prophylaxis against recurrent UTI. Each of the studies compared D-mannose use with no
prophylactic therapy or other conventional prophylactic methods. Prior to initiation of
prophylaxis, all studies enrolled patients with acute cystitis; patients were treated as described
later. In two studies, subjects were considered cured if they reported resolution of symptoms and
had a negative urine culture. The third study considered patients cured if they did not report
persistence of symptoms after treatment. The focus of this review is on the follow-up period after
treatment and cure of acute cystitis when subjects were monitored for recurrence of UTI while
using D-mannose for prophylaxis or other methods. Refer to Table 2 for comparison of
recurrence of UTI in women with varying interventions in all RCTs.
Table 2. Number of patients having a recurrent UTI across all 3 RCTs
Group

D-mannose
No prophylaxis
D-mannose
No prophylaxis
D-mannose
TMP-SMX

Number of Patients
P-value
having recurrence of
UTI
Domenici et al.
1 (4.5%)
P < 0.05
7 (33.3%)
Krancjec et al.
15 (14.5%)
P < 0.001
62 (60.7%)
Porru et al.
12 (20%)
P < 0.0001
45 (75%)

Numbers needed to
treat (NNT)

4

3

2

Domenici et al. studied women with acute cystitis or asymptomatic culture-proven UTI
and a history of recurrent UTI. Subjects were treated for acute UTI with D-mannose 1.5 g twice
per day for 3 days and then once daily for 10 days. Patients were considered cured if they
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reported symptom cure according to the Urinary Tract Infections Symptoms Assessment
(UTISA). This was confirmed with urine culture. Cured subjects were then split into two groups
for prophylaxis. Twenty-two subjects received D-mannose 1.5 g once a day for 1 week every
other month for 6 months and 21 women received nothing. A statistically significant difference
between the groups was observed. In the treatment group, 1 (4.5%) had a recurrence, while in the
control group 7 (33.3%) had recurrence, P<0.05.6 This study showed a large treatment effect with
NNT equal to 4.
Kranjcec et al. studied women who had acute cystitis and a history of recurrent UTI.
Patients were considered to have an acute infection if they reported at least two irritative voiding
symptoms. This was confirmed with a positive urine culture defined as >103 CFU in a cleancatch specimen. Initial UTI was treated with ciprofloxacin 500 mg daily for 7 days and cure was
defined as no lower urinary tract symptoms (LUTS) and <103 CFU on urine culture. Patients
were then randomized to three groups and monitored for 6 months. The first group received 2 g
D-mannose once daily at night. The second group was given nitrofurantoin 50 mg once daily at
night. The third group was given nothing. If a patient reported LUTS during the follow-up
period, she was said to have a recurrence, but urine culture was also performed.2
In the D-mannose group, 15 (14.5%) reported recurrence. In the nitrofurantoin group, 21
(20.3%) reported recurrence. In the group receiving no prophylaxis, 62 (60.7%) reported
recurrence. The number of recurrent episodes was statistically different between the group with
no prophylaxis and those with either D-mannose or nitrofurantoin (P< 0.001). Risk reduction
(RR) of recurrent cystitis episode in the D-mannose group compared with the no prophylaxis
group was 0.239 and was statistically significant (95% CI 0.146-0.392, P <0.0001). Risk
reduction of nitrofurantoin and no prophylaxis was 0.335 and statistically significant (95% CI
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0.222-0.506, P<0.0001). D-mannose showed a large treatment effect compared to no prophylaxis
with NNT equal to 3. Importantly, this study shows a decreased risk of recurrence with Dmannose than nitrofurantoin as reported in Table 3, but these two values may not be statistically
different.2
Table 3. Risk Reduction of Recurrent Cystitis D-mannose vs Nitrofurantoin
Intervention
D-mannose
Nitrofurantoin

RR
0.239
0.335

95% CI
0.146-0.392
0.222-0.506

P-value
P < 0.0001
P < 0.0001

Porru et al. studied females with acute cystitis and a history of three or more documented
UTIs in the last year. One group was treated with trimethoprim-sulfamethoxazole (TMP-SMX)
160/800 mg twice a day for 5 days then once daily at night for one week of each month for 23
weeks. The second group was treated with D-mannose 1 g three times a day for 2 weeks then 1 g
twice daily for 22 weeks. At the end of the 24-week period, the subjects switched groups and
were studied for an additional 24 weeks. Subjects were considered to have recurrence if new
symptoms arose. In the D-mannose group, 12 (20%) had a UTI recurrence, while in the TMPSMX group, 45 (75%) had a recurrence. This study showed a large treatment effect with Dmannose with NNT equal to 2. Under D-mannose mean TTR was 200 days (SD 50.7) and under
TMP-SMX, mean TTR was 52.7 days (SD 11.2) and the difference was statistically significant
(p<0.0001).7 Refer to Table 4.
Table 4. Time to Recurrence of UTI TMP-SMX vs D-mannose
Group
D-mannose
TMP-SMX

Mean Time to
Recurrence
200 days
52.7 days

SD

P-value

50.7
11.2

P < 0.001
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Secondarily, Porru et al. recorded patients’ descriptions of their pain and urgency on the
visual analog scale (VAS). Prior to D-mannose treatment mean VAS pain was 4.4 (SD 1.1) and
after treatment was 2.2 (SD 0.5). Mean VAS urgency before D-mannose was 4.6 (SD 1.1) and
after was 2.6 (SD 0.7). These differences were statistically significant (p<0.001). Refer to Table
5. VAS differences were not reported for the TMP-SMX group. However, this shows that Dmannose not only prevents recurrence, but gives patients an improved sense of symptoms and
irritation from recurrent infection. This is an important component for evaluating effectiveness of
prophylactic therapy given the known psychologic distress caused by recurrent UTIs.7
Table 5. VAS Pain and Urgency Before and After Treatment with D-mannose

Before Treatment
After Treatment

VAS Pain
4.4 (SD 1.1)
2.2 (SD 0.5)

VAS Urgency
4.6 (SD 1.1)
2.6 (SD 0.7)

P-value
P < 0.001

Adverse effects were reported by Krancjec et al. During the 6-month follow-up period,
37 out of 206 patients (17.9%) reported side effects, but none were severe enough to warrant
stopping therapy. In the D-mannose group, 8 patients (7.8%) reported diarrhea. No other side
effects were reported in this group. In the nitrofurantoin group, 29 patients (28%) reported side
effects. Of these, 10 reported diarrhea, 6 reported nausea, 3 headache, 1 skin rash, and 9 vaginal
burning. See Table 6. Patients in the D-mannose group had a lower risk of side effects compared
to nitrofurantoin and the difference was statistically different (RR 0.276, 95% CI 0.132-0.574, P
< 0.0001).2 See Table 7. Domenici et al. had no reported side effects during treatment or
prophylaxis with D-mannose.6 Porru et al. make no mention of adverse effects.7
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Table 6. Number of Patients with Adverse Effects of Prophylaxis
Adverse Effect
Diarrhea
Nausea
Headache
Skin Rash
Vaginal Burning

D-mannose group (number
of patients reporting)
8
0
0
0
0

Nitrofurantoin (number of
patients reporting)
10
6
3
1
9

Table 7. Risk reduction for side effects D-mannose compared to Nitrofurantoin
RR
0.276

95% CI
0.132-0.574

P-value
P < 0.0001

DISCUSSION
Recurrent urinary tract infections are a costly part of healthcare in the United States. In
addition, these infections cause significant distress in affected women. Adequate prophylaxis
measures that are both safe and effective are necessary to prevent continued recurrence of
infection. Further, the advent of antibiotic resistance and the limited options for treating UTIs
necessitate a safe and natural approach to preventing recurrent UTI. The primary objective of
this systematic review was to evaluate the effectiveness of D-mannose as prophylaxis against
UTI recurrence. Briefly explored, were patients’ impressions of their relief of common
symptoms of UTI, and safety and tolerability of D-mannose.
Each of the studies had limitations that must be addressed. First, none of the studies were
blinded. Domenici et al. and Krancjec et al. did not offer placebo to patients receiving no
prophylaxis. Further, Porru et al. employed a crossover study that had different dosing regimens
for the interventions used, making it easy to tell that the two treatments were different.
Randomized, double-blinded studies should be pursued to better evaluate the effectiveness of D-
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mannose for prophylaxis against recurrent UTI. Further, each of the studies had relatively small
patient populations. Studies involving more subjects with blinding should be conducted.
An important limitation of Porru et al. is that trimethoprim-sulfamethoxazole (TMPSMX) was given less frequently and in lesser amount than D-mannose during the 24-week
follow-up period. The study shows that D-mannose can effectively prevent recurrent urinary
tract infection with only 20% of patients reporting recurrence with D-mannose. However, TMPSMX 160/800 was dosed once daily at night for one week each month for 6 months while Dmannose was dosed 1 g twice daily. This inconsistency in dosing between the two agents limits
the ability to regard one superior to the other. Recommendations for prophylactic regimens with
TMP-SMX have not been concretely established, but empiric prophylaxis is most commonly
low-dose TMP-SMX (80/400 or 40/200) nightly for 6 months.1 Dosing according to the current
recommendation should be used for adequate comparison of the two agents.
Another limitation is that all three studies used different doses of D-mannose for
prophylaxis. Domenici et al. used 1.5 g nightly one week every other month for 6 months.
Kranjcec et al. used 2 g nightly for 6 months, and Porru et al. used 1 g twice daily for 6 months.
There has not yet been an established standard dose for D-mannose for prophylaxis of recurrent
UTI but recommendations vary from 500 mg daily to 2 g daily in single or divided doses.2,8
Further studies should be done to investigate optimal dosage.
Regarding cost, D-mannose is an over-the-counter supplement that is not covered by
insurance. However, it is an affordable over-the-counter alternative. To address tolerability,
patients reported side effects that were minimal or absent in the studies, making this supplement
safe and feasible for long-term use. Of note, while D-mannose is a sugar similar to glucose, it is
not able to be converted to glycogen and therefore is not stored in the body.6 Long-term use of
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this product, even in high concentrations, has shown no ill effects on metabolic function.6 Since
this sugar has no effect on metabolism, its chronic use is of no concern for causing
hyperglycemia, obesity, or metabolic disorders.8 Importantly, it can be considered safe in
diabetic patients or those avoiding sugars for other reasons.8
CONCLUSIONS
All three studies demonstrated that D-mannose is an effective prophylactic agent for
recurrent UTIs in women who are prone to these infections. There was a significant difference
between D-mannose and no agent for prophylaxis in two studies. D-mannose also showed a large
treatment effect across all three studies. What cannot be determined from these studies is
whether D-mannose is superior to nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX)
in terms of efficacy. D-mannose shows similar efficacy to nitrofurantoin; however, it does
appear superior in terms of safety and tolerability. Studies evaluating D-mannose compared to
TMP-SMX using appropriate and comparable dosing of the two agents must be pursued. Further
studies should investigate D-mannose for recurrent UTI prophylaxis in larger patient
populations, and should seek to establish the most effective dosing regimen. Lastly, D-mannose
does improve patient perception of symptoms as reported in one study, demonstrating that it may
help decrease psychologic distress associated with recurrent UTI. Ultimately, D-mannose shows
promise as an effective supplement that can prevent distressing recurrent UTIs, but it does
require further study before becoming standard of care for all patients.
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